DBVT
NASD DBV Technologies SA Sponsored ADR$11.21 ↑ +0.00 (+0.00%) Trading Up from the previous close of $11.21, $0.37 below the day’s high of $11.58
- YTD change
- -41.52%
- vs 20-day SMA
- -9.63%
- vs 200-day SMA
- -37.53%
Price ranges
Price & Performance
-8.74 (-42.63%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.8% away from all-time highs of $505.70
- DBVT is down 42% since the beginning of the year
- DBVT is up 11% over the past 12 months
- DBVT is down 16% over the past 1 month
- 2% of all DBVT investors are betting against DBVT
DBVT reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +16.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -7.89%
- vs 8-day SMA
- -5.61%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
